Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AlloVir (ALVR)
NASDAQ:ALVR
Holding ALVR?
Track your performance easily
ALVR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.58 - $2.49
Previous Close$0.62
Volume2.16M
Average Volume (3M)247.29K
Market Cap
$111.30M
Enterprise Value-$9.31M
Total Cash (Recent Filing)$129.61M
Total Debt (Recent Filing)$9.00M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Oct 31, 2024EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding115,365,282
10 Day Avg. Volume747,395
30 Day Avg. Volume247,288
Standard Deviation0.23
R-Squared0.02
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.59
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.08
Forecast
1Y Price Target
$0.50Price Target Upside-19.22% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
AlloVir News
PremiumCompany Announcements
AlloVir and Kalaris Merge to Advance Retinal Therapies
PremiumCompany Announcements
AlloVir Finalizes $7 Million Lease Termination Deal
PremiumCompany Announcements
AlloVir Ends Lease Agreement with AMAG Pharmaceuticals
PremiumCompany Announcements
AlloVir Approves Executive Bonuses for Potential 2024 Buyout
PremiumCompany Announcements
AlloVir Faces Delisting Risk, Considers Reverse Split to ComplyBulls Say, Bears Say
Bulls Say
Financial ResilienceALVR ended 2Q24 with $105.3 million in cash and equivalents, providing strong financial stability.
Operational FundingALVR has sufficient cash and equivalents to fund operations for an extended period, showcasing robust financial health.
Strategic ReviewUpcoming catalysts include the outcome of the review of strategic alternatives, which could impact the company’s future direction.
Bears Say
R&D ExpensesR&D expenses were significantly higher than estimates, which could indicate increased costs.
SG&A ExpensesSG&A expenses were above estimates, suggesting unexpected operational costs.
Strategic ReviewNo updates were provided on the timetable for the strategic review process.
---
Ownership Overview
Currently, No data available
---
ALVR FAQ
What was AlloVir’s price range in the past 12 months?
AlloVir lowest stock price was $0.58 and its highest was $2.48 in the past 12 months.
What is AlloVir’s market cap?
Currently, no data Available
When is AlloVir’s upcoming earnings report date?
AlloVir’s upcoming earnings report date is Oct 31, 2024 which is 10 days ago.
How were AlloVir’s earnings last quarter?
AlloVir released its earnings results on Aug 01, 2024. The company reported -$0.05 earnings per share for the quarter, the consensus estimate of -$0.05 by $0.
Is AlloVir overvalued?
According to Wall Street analysts AlloVir’s price is currently Overvalued.
Does AlloVir pay dividends?
AlloVir does not currently pay dividends.
What is AlloVir’s EPS estimate?
AlloVir’s EPS estimate is -$0.1.
How many shares outstanding does AlloVir have?
AlloVir has 115,365,280 shares outstanding.
What happened to AlloVir’s price movement after its last earnings report?
AlloVir reported an EPS of -$0.05 in its last earnings report, expectations of -$0.05. Following the earnings report the stock price went up 4.494%.
Which hedge fund is a major shareholder of AlloVir?
Among the largest hedge funds holding AlloVir’s share is Graham Capital Management, L.P.. It holds AlloVir’s shares valued at N/A.
---
AlloVir Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$0.50 (-19.22% Downside)
$0.50 (-19.22% Downside)
Blogger Sentiment
Bullish
ALVR Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $40.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.6%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-60.32%
12-Months-Change
Fundamentals
Return on Equity
-80.33%
Trailing 12-Months
Asset Growth
-53.66%
Trailing 12-Months
Company Description
AlloVir
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
---
ALVR Stock 12 Month Forecast
Average Price Target
$0.50
▼(-19.22% Downside)
Technical Analysis
Best Analysts Covering ALVR
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-49.56%
downgraded a sell rating 11 months ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -49.56% per trade.
---